Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

March 16, 2023 | Brand Strategy, Digital, Healthcare Technology, biotech, digital health, digital therapeutics, wearables 

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?

By 2026, the number of people using digital therapeutics is estimated to increase by 381%, reaching a market size of $28 billion. This makes digital therapeutics the fastest-growing field in digital health.

Digital therapeutics are evidence-based therapeutic interventions, designed to prevent, manage, or treat a variety of medical conditions, ranging from chronic diseases and neurological disorders to tackling challenges such as medication adherence.

The benefits are far-reaching, from optimizing patient outcomes to reducing the economic burden on healthcare systems. However, the real value lies when digital therapeutics are combined with a medicinal asset. This powerful combination uncovers a wealth of untapped opportunities for biopharmaceutical companies to maximize the value of medicinal assets, driving differentiation and increasing access to safe and effective therapies.

To capitalize on this opportunity, the digital therapeutic must support an asset to fulfill an unmet need. However, as tech giants shape this arena and more needs are catered to, it will become difficult to develop digital platforms that increase value for all stakeholders. As a result, early market entry is fundamental.

In this whitepaper, Fishawack Health consultants explore the market landscape and provide strategic recommendations for manufacturers to leverage the power of digital therapeutics to enhance the value of products and portfolios including:

  • Digital therapeutics market growth 
  • Key therapy areas and applications
  • Detailed benefits for stakeholders and advice on overcoming adoption hurdles
  • Strategic recommendations for developing a digital therapeutics commercialization strategy that crystalizes the value of an asset

DOWNLOAD THE WHITEPAPER HERE

This content was provided by Avalere Health

Company Details

- PMLiVE

Avalere Health

Email
Website

 Latest Content from  Avalere Health 

Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies

Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

Archetypes: Rethinking go-to-market expectations to drive commercial success

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer

Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

The challenges of reimbursement and innovative pricing for cell and gene therapies

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.